Reduced mu opioid receptor availability in schizophrenia revealed with [11C]-carfentanil Positron Emission Tomographic Imaging

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)
109 Downloads (Pure)

Abstract

Negative symptoms, such as amotivation and anhedonia, are a major cause of functional impairment in schizophrenia. There are currently no licensed treatments for negative symptoms, highlighting the need to understand the molecular mechanisms underlying them. Mu-opioid receptors (MOR) in the striatum play a key role in hedonic processing and reward function and are reduced post-mortem in schizophrenia. However, it is unknown if mu-opioid receptor availability is altered in-vivo or related to negative symptoms in schizophrenia. Using [11C]-carfentanil positron emission tomography (PET) scans in 19 schizophrenia patients and 20 age-matched healthy controls, here we show a significantly lower MOR availability in patients with schizophrenia in the striatum (Cohen's d= 0.7), and the hedonic network. In addition, we report a marked global increase in inter-regional covariance of MOR availability in schizophrenia, largely due to increased cortical-subcortical covariance.
Original languageEnglish
Article number4493
Number of pages9
JournalNature Communications
Volume10
Issue number1
Early online date3 Oct 2019
DOIs
Publication statusPublished - 3 Oct 2019

Fingerprint

Dive into the research topics of 'Reduced mu opioid receptor availability in schizophrenia revealed with [11C]-carfentanil Positron Emission Tomographic Imaging'. Together they form a unique fingerprint.

Cite this